The Week in Review: Major Cross-Border Initiatives

The BioBay Investor Forum selected BeiGene LLC and Suzhou KeyBay Biotech as the two “Most Promising” China early stage life science companies presenting at its November 3-4 conference; Eli Lilly will build a bricks and mortar in-house R&D center in Shanghai dedicated to diabetes drugs; Nycomed bought a majority 51.3% stake in Guangdong Techpool Bio-Pharma; Simcere Pharma partnered with Bristol-Myers Squibb to co-develop a cancer molecule; Fibrocell Science set up a joint venture with Hefei Meifu Bio-Tech; Swedish Orphan Biovitrum in-licensed European marketing rights for an anemia drug from Dongbao Group; D-Pharm of Israel enlisted China CRO Tigermed for a Phase III clinical trial of its stroke treatment; NeoStem’s stem cell-based orthopedic treatment was approved in Weihai; and Tongjitang Chinese Medicines will be taken private by a group comprised of its Chairman and Fosun Industrial. More details…. Stock Symbols: (NYSE: LLY) (NYSE: SCR) (NYSE: BMY) (OTCBB: FCSC) (STO: SOBI) (SHEX: 600867) (TASE: DPRM) (NYSE Amex: NBS) (NYSE: TCM)